Search results
Results from the WOW.Com Content Network
Atypical ductal hyperplasia (ADH) is the term used for a benign lesion of the breast that indicates an increased risk of breast cancer. [1]The name of the entity is descriptive of the lesion; ADH is characterized by cellular proliferation (hyperplasia) within one or two breast ducts and (histomorphologic) architectural abnormalities, i.e. the cells are arranged in an abnormal or atypical way ...
Atypical hyperplasia is a high-risk premalignant lesion of the breast. It is believed that atypical ductal hyperplasia (ADH) is a direct precursor for low-grade mammary ductal carcinoma , whereas atypical lobular hyperplasia (ALH) serves as a risk indicator.
Atypical ductal hyperplasia is associated with a 2.4-fold risk. [20] In contrast, a New England Journal of Medicine article [ 21 ] states that for women with a strong familial history of breast cancer, the risk of future breast cancer is roughly doubled, independent of histological status.
Invasive carcinoma NST is a type of breast cancer. It is one of the invasive breast cancers that originates from the breast ductal system, so that it is a type of ductal carcinoma. A defining feature of this ductal carcinoma is that it lacks the "specific differentiating features" of other types of ductal carcinomas.
Examples include atypical ductal hyperplasia, atypical lobular hyperplasia, and intraductal papillomas. References. External links. Benign ...
Presence of high-risk breast lesions like lobular carcinoma in situ (LCIS), atypical ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH). [7] Having dense breasts or breasts with diffuse microcalcification, as the screening for breast cancer is made difficult.
Hyperplasia of the breast – "Hyperplastic" lesions of the breast include usual ductal hyperplasia, a focal expansion of the number of cells in a terminal breast duct, and atypical ductal hyperplasia, in which a more abnormal pattern of growth is seen, and which is associated with an increased risk of developing breast cancer. [2]
Staging breast cancer is the initial step to help physicians determine the most appropriate course of treatment. As of 2016, guidelines incorporated biologic factors, such as tumor grade, cellular proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression profiling into the staging system.